Search Results

Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, announces that it has enrolled the first eight of 32 patients in a Phase 2a clinical study of its lead asset BIOX-101.

Bioxodes SA announces it has received a notice from the European Patent Office of its intention to grant a patent for the lead asset of Bioxodes, BIOX-101, further broadening the candidate therapy’s protection in thromboinflammation, and adding to the company’s strong portfolio of intellectual property rights, which include a related approval in Australia, dating from June 2022, and a pending patent grant from Russia’s Center for Intellectual Property Rights.

Bioxodes SA, a company specializing in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today announces it has been selected to present at key international business and scientific conferences this spring and early summer:

OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months.